Facon et al identified pretreatment prognostic factors associated with survival in patients with Waldenstrom's Macroglobulinemia. Patients with one or more high risk factors might benefit from more aggressive therapy. The study was done in Lille, France.
Pretreatment factors associated with shorter survival when treated with low-dose chlorambucil:
(1) age >= 60 years
(2) male sex
(3) hemoglobin < 10 g/dL
(4) neutrophils < 1.7 * 10^9/L (< 1,700 per µL)
Additional factors associated with shorter survival:
